ciprofloxacin has been researched along with Obstructive Lung Diseases in 14 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The sputum pharmacokinetics and clinical efficacy of ciprofloxacin in lower respiratory tract infections is reviewed." | 10.16 | Clinical efficacy of ciprofloxacin in lower respiratory tract infections. ( Pedersen, SS, 1989) |
| "The efficacy and safety of oral temafloxacin (600 mg) and ciprofloxacin (500 mg) twice daily for seven days were compared in patients with mild to moderate lower respiratory tract infections." | 9.07 | Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicenter, double-blind, randomized study. ( Chodosh, S, 1991) |
| "The sputum pharmacokinetics and clinical efficacy of ciprofloxacin in lower respiratory tract infections is reviewed." | 6.16 | Clinical efficacy of ciprofloxacin in lower respiratory tract infections. ( Pedersen, SS, 1989) |
| " The higher dosage showed a reduced amount of reinfections and relapses (19% and 16% versus 5% and 0%)." | 5.28 | Two different dosages of ciprofloxacin in patients with respiratory tract infections. ( Brutel de la Rivière, T; Daniëls-Bosman, MS; ten Velde, GP, 1989) |
| "The efficacy and safety of oral temafloxacin (600 mg) and ciprofloxacin (500 mg) twice daily for seven days were compared in patients with mild to moderate lower respiratory tract infections." | 5.07 | Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicenter, double-blind, randomized study. ( Chodosh, S, 1991) |
| "The lower respiratory tract infections caused by E." | 2.68 | [The clinical manifestation and drug sensitive tests of lower respiratory tract infection by enterobacter cloacae. The Pulmonary Infection and Fibrosis Group, Thoracic Society Shanghai Medical Association]. ( , 1997) |
| " Sufficient dosage might control early formation of biofilms." | 1.35 | Activity of ciprofloxacin and azithromycin on biofilms produced in vitro by Haemophilus influenzae. ( Liu, YN; Wang, D; Wang, Y, 2009) |
| " The higher dosage showed a reduced amount of reinfections and relapses (19% and 16% versus 5% and 0%)." | 1.28 | Two different dosages of ciprofloxacin in patients with respiratory tract infections. ( Brutel de la Rivière, T; Daniëls-Bosman, MS; ten Velde, GP, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 10 (71.43) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, D | 1 |
| Wang, Y | 1 |
| Liu, YN | 1 |
| Echevarria, KH | 1 |
| Barriere, SL | 1 |
| Hindler, JA | 1 |
| Pan, XS | 1 |
| Ambler, J | 1 |
| Mehtar, S | 1 |
| Fisher, LM | 1 |
| Hasani, A | 1 |
| Pavia, D | 1 |
| Rotondetto, S | 1 |
| Clarke, SW | 1 |
| Spiteri, MA | 1 |
| Agnew, JE | 1 |
| Zuck, P | 1 |
| Weber, P | 1 |
| Umut, S | 1 |
| Tutluoglu, B | 1 |
| Aydin Tosun, G | 1 |
| Müsellim, B | 1 |
| Erk, M | 1 |
| Yildirim, N | 1 |
| Vahapoglu, H | 1 |
| Yilmaz, N | 1 |
| Arseven, O | 1 |
| Türker, H | 1 |
| Erelel, M | 1 |
| Ilvan, A | 1 |
| Göylüsün, V | 1 |
| Yilmaz Kuyucu, T | 1 |
| Koşar, F | 1 |
| Soysal, F | 1 |
| Gür, A | 1 |
| Unutmaz, S | 1 |
| Oztürk, S | 1 |
| Akman, M | 1 |
| Chodosh, S | 1 |
| Basran, GS | 1 |
| Joseph, J | 1 |
| Abbas, AM | 1 |
| Hughes, C | 1 |
| Tillotson, GS | 1 |
| Pedersen, SS | 1 |
| Brutel de la Rivière, T | 1 |
| Daniëls-Bosman, MS | 1 |
| ten Velde, GP | 1 |
| Wijnands, WJ | 1 |
| Vree, TB | 1 |
| Baars, AM | 1 |
| van Herwaarden, CL | 1 |
1 review available for ciprofloxacin and Obstructive Lung Diseases
| Article | Year |
|---|---|
Clinical efficacy of ciprofloxacin in lower respiratory tract infections.
Topics: Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Interactions; Humans; Lung Diseases, | 1989 |
6 trials available for ciprofloxacin and Obstructive Lung Diseases
| Article | Year |
|---|---|
Effect of oral antibiotics on lung mucociliary clearance during exacerbation of chronic obstructive pulmonary disease.
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Cough; Double-Blind Method; Female; Forced Expira | 1998 |
[The clinical manifestation and drug sensitive tests of lower respiratory tract infection by enterobacter cloacae. The Pulmonary Infection and Fibrosis Group, Thoracic Society Shanghai Medical Association].
Topics: Adult; Aged; Amikacin; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Enterobacter | 1997 |
Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor. Turkish Thoracic Society COPD Working Group.
Topics: Ampicillin; Anti-Infective Agents; Azithromycin; Cefaclor; Ciprofloxacin; Drug Therapy, Combination; | 1999 |
Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicenter, double-blind, randomized study.
Topics: Ambulatory Care; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones | 1991 |
Treatment of acute exacerbations of chronic obstructive airways disease--a comparison of amoxycillin and ciprofloxacin.
Topics: Amoxicillin; Ciprofloxacin; Female; Haemophilus influenzae; Humans; Lung Diseases, Obstructive; Male | 1990 |
Clinical efficacy of ciprofloxacin in lower respiratory tract infections.
Topics: Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Interactions; Humans; Lung Diseases, | 1989 |
8 other studies available for ciprofloxacin and Obstructive Lung Diseases
| Article | Year |
|---|---|
Activity of ciprofloxacin and azithromycin on biofilms produced in vitro by Haemophilus influenzae.
Topics: Anti-Bacterial Agents; Azithromycin; Biofilms; Ciprofloxacin; Haemophilus influenzae; Humans; Lung D | 2009 |
A warning on the use of Cipro.
Topics: Aged; Ciprofloxacin; Drug Interactions; Humans; Lung Diseases, Obstructive; Theophylline | 1994 |
Ciprofloxacin-resistant Haemophilus influenzae infection in a patient with chronic lung disease.
Topics: Adult; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; Haemophilus Infections; Haemophil | 1993 |
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
Topics: Amino Acid Sequence; Anti-Infective Agents; Base Sequence; Ciprofloxacin; DNA Topoisomerase IV; Gene | 1996 |
[The role of ciprofloxacin in the treatment of chronic bronchitis].
Topics: Acute Disease; Anti-Infective Agents; Bacterial Infections; Bronchitis; Chronic Disease; Ciprofloxac | 1998 |
[Bacteriology in community-acquired respiratory pathology].
Topics: Acute Disease; Ambulatory Care; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprof | 1998 |
Two different dosages of ciprofloxacin in patients with respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Ciprofloxacin; Female; Humans; Lung Diseases, Obstructive; Male; Mid | 1989 |
The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Lung Diseases, Obstructive; Male; Metabo | 1987 |